Deeptech Digest | News about deeptech

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel...

World’s largest clinically linked spatial biology atlas launched

Jim Cornall - April 2, 2026

Bioptimus has announced the launch of its Spatial Tissue Embedding Learning Atlas (STELA), a multinational spatial data generation initiative...

Changing the search for rare disease diagnoses with AI breakthrough

Jim Cornall - April 2, 2026

A newly developed AI tool can speed up the search for the genetic causes of rare diseases, a process...

Precision medicine helps more patients receive genetic diagnosis

Jim Cornall - April 1, 2026

A collaboration between Karolinska Institutet, Karolinska University Hospital, and SciLifeLab has integrated whole genome sequencing into routine diagnostic investigations...

Tumour DNA in blood after pre-surgery treatments predicts if breast cancer will return

Jim Cornall - April 1, 2026

Fragments of tumour DNA in the bloodstream of patients with breast cancer can predict whether they are likely to...

Radiotherapy may help reduce risk of lymphoedema in patients with breast cancer

Jim Cornall - April 1, 2026

Patients with breast cancer may be able to avoid lymphoedema, which can occur after surgery to remove lymph nodes...

UCB picks Rowen as $2bn manufacturing campus

Jim Cornall - March 31, 2026

The State of Georgia, Gwinnett County and the Rowen Foundation have announced that global biopharmaceutical company UCB has selected...

Researchers move closer to preventing pandemics

admin - March 31, 2026

Researchers have developed an AI tool that can help determine whether unfamiliar bacteria carry genetic features linked to disease....

Copper overload kills cancer cells

Jim Cornall - March 31, 2026

Cuproptosis was discovered in 2022. It was a previously unknown type of cell death caused by an excess of...

Lyme disease vaccine shows strong efficacy in phase 3 trial

Jim Cornall - March 30, 2026

Pfizer Inc. and Valneva SE have announced topline results from the phase 3 VALOR (Vaccine Against Lyme for Outdoor...

FDA approves pill for plaque psoriasis

Jim Cornall - March 30, 2026

Johnson & Johnson has announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra), an...

Crossbow Therapeutics raises $77m to treat cancer

Jim Cornall - March 30, 2026

Crossbow Therapeutics, Inc. has raised $77m in a Series B financing that will support the completion of the CROSSCHECK-001...

Base to Base biotech podcast 52: Ketamine for depression, and a new company in the kidney disease space

Jim Cornall - March 27, 2026

On this week’s episode, we chat with Hans Eriksson, chief medical officer (CMO) of HMNC Brain Health, about ketamine...

Excalipoint Therapeutics launches with $68.7m to develop T-Cell engager therapies

Jim Cornall - March 26, 2026

Excalipoint Therapeutics has announced an oversubscribed $68.7m seed financing round to support advancement of its proprietary technology platforms and...

FDA clearance for refractory gout treatment

Jim Cornall - March 26, 2026

Innorna has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application...

Earendil Labs raises $787m to scale AI-driven biologics discovery and development

Jim Cornall - March 26, 2026

Earendil Labs has raised $787m in financing rounds. The funding will accelerate Earendil Labs' AI-driven R&D platform, expand its...

Researchers design drug capable of reversing cognitive decline in Alzheimer’s disease

Jim Cornall - March 25, 2026

A team from the University of Barcelona has designed and validated in animal models a compound with a pioneering...

Shingles vaccine cuts risk of serious cardiac events

Jim Cornall - March 25, 2026

People with heart disease who received a shingles vaccine had nearly half the rate of serious cardiac events a...

Initial data suggest favourable safety profile for Alzheimer’s drug

Jim Cornall - March 25, 2026

Priavoid GmbH has announced promising initial safety data from its ongoing phase 2 trial (PRImus-AD) evaluating its lead candidate,...

Positive results from second-line metastatic breast cancer trial

Jim Cornall - March 24, 2026

Pfizer Inc. has announced positive topline results from the randomised phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with...

Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer

Jim Cornall - March 24, 2026

Outrun Therapeutics, a biotech developing protein stabilising therapeutics identified by its proprietary XL discovery platform, has selected its lead...